Novartis to Resolve Texas, U.S. Eczema Drug Probe

Novartis AG agreed to pay $19.9 million to the U.S. and Texas in settlement of claims that it unlawfully marketed Elidel, a topical cream used to treat eczema.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.